References
- Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5065 grafts related to survival and reoperation in 1388 patients during 25 y. J Am Coll Cardiol 1996; 28: 616–26.
- Korpilahti K, Engblom E, Hämäläinen H, Syvänne M, Hietanen E, Arstila M, et al. Significance of graft occlusion and coronary atherosclerosis 5 y after coronary artery bypass grafting. A quantitative angiographic study with serial exercise testing. J Intern Med 1999; 245: 545–52.
- Schweiger MJ, Roccario E, Weil T. Treatment of patients following bypass surgery: a dilemma for the 1990s. Am Heart J 1992; 123: 268–72.
- Mills NL, Evenson CT Vein graft failure. Curr Opin Cardiol 1995; 10: 562–8.
- Cox JL, Chiasson DA, Gotlieb AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis 1991; 34: 45–68.
- Morton KE, Gavaghan TP, Krilis SA, Daggard GE, Baron DW, Hickie JB, Chesterman CN. Coronary artery bypass graft failure: an autoimmune phenomenon? Lancet 1986; 2: 1353–7.
- Limnell V, Aittoniemi J, Vaarala O, Lehtimaki T, Laine S, Virtanen V, et al. Association of mannan-binding lectin deficiency with venous bypass graft occlusion in patients with coronary heart disease. Cardiology 2002; 98: 123–6.
- Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. Br Med J 1998; 316: 1130–2.
- Mayr M, Kiechl S, Willeit J, Wick G, Xu Q. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 2000; 102: 833–9.
- Siscovick DS, Schwartz SM, Corey L, Grayston JT, Ashley R, Wang SP, et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: the cardiovascular health study. Circulation 2000; 102: 2335–40.
- Nobel M, de Torrente A, Peter O, Genne D. No serological evidence of association between Chlamydia pneumoniae infection and acute coronary heart disease. Scan J Infect Dis 1999; 31: 261–4.
- Shimada K, Mokuno H, Watanabe Y, Sawano M, Daida H, Yamaguchi H. High prevalence of seropositivity for antibodies to Chlamydia-specific lipopolysaccharide in patients with acute coronary syndrome. J Cardiovasc Risk 2000; 7: 209–13.
- Perussia B, Loza MJ. Linear ‘2–0–1’ lymphocyte development: hypotheses on cellular bases for immunity. Trends Immunol 2003; 24: 235–41.
- Kohler HP, Grant PJ. Mechanisms of disease: plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792–801.
- Riccioni G, De Santis A, Cerasa V, Menna V, Di Ilio C, Schiavone C, et al. Atherosclerotic plaque formation and risk factors. Int J Immunopathol Pharmacol 2003; 16: 25–31.
- Kosunen TU, Seppälä K, Sarna S, Sipponen P Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet 1992; 339: 893–5.
- Cullen DJ, Cullen KJ, Collins BJ, Christiansen KJ, Epis J. Serological assessment of Helicobacter pylori eradication. Lancet 1992; 340: 1161–2